

## Notice Regarding Adjustment of 340B Prices for Select Products of Xellia Pharmaceuticals USA, LLC

Xellia has recalculated its 340B ceiling prices for the period from Q1 2022 through Q3 2024 for the products listed below due to revisions made to their Medicaid pricing data. Xellia has asked the Office of Pharmacy Affairs (OPA) within HRSA to post this Notice on the public website to ensure transparency by providing access to information about Xellia's recalculation affecting certain 340B Covered Entities for the impacted product(s).

Xellia has determined the credit amount owed to each affected covered entity. Xellia will be working through Apexus to issue refunds for each affected Covered Entity that is owed \$25 or more. Refunds will be issued either to a Covered Entity's validated wholesaler pharmacy account when one can be identified, or a check or ACH will be issued to Covered Entities whose wholesaler account cannot be identified.

NDC	Product Description
70594-0023-01	COLISTIMETHATE 150MG
70594-0023-04	COLISTIMETHATE 150MG
70594-0034-01	DAPTOMYCIN 500MG
70594-0036-01	MICAFUNGIN 50MG
70594-0037-01	MICAFUNGIN 100MG
70594-0041-03	VANCOMYCIN RTU 500MG
70594-0042-03	VANCOMYCIN RTU 1GM
70594-0043-02	VANCOMYCIN RTU 1.5GM
70594-0044-02	VANCOMYCIN RTU 2GM
70594-0045-02	VANCOMYCIN HCL 500MG
70594-0046-02	VANCOMYCIN HCL 1GM
70594-0047-01	VANCOMYCIN HCL 5GM
70594-0048-01	VANCOMYCIN HCL 10GM
70594-0049-02	POLYMYXIN B
70594-0053-01	DAPTOMYCIN 350MG
70594-0056-03	VANCOMYCIN RTU 750MG
70594-0057-02	VANCOMYCIN RTU 1.25GM
70594-0058-02	VANCOMYCIN RTU 1.75GM
70594-0063-02	PHENYLEPHRINE HCL 10MG
70594-0066-01	DAPTOMYCIN 350MG
70594-0068-02	SUMATRIPTAN 6MG
70594-0072-02	NEOSTIGMINE METHYLSULFATE 1MG

70594-0075-02	MEROPENEM 500MG
70594-0076-02	MEROPENEM 1GM
70594-0078-02	PIPERACILLIN 2G TAZOBACTAM 250MG
70594-0079-02	PIPERACILLIN 2G TAZOBACTAM 375MG
70594-0080-02	PIPERACILLIN 4G TAZOBACTAM 500MG
70594-0081-02	AMPICILLIN 1G AND SULBACTAM 500MG
70594-0082-02	AMPICILLIN 2G AND SULBACTAM 1G
70594-0084-02	AMPICILLIN 250MG
70594-0085-02	AMPICILLIN 500MG
70594-0086-02	AMPICILLIN 1G
70594-0087-02	AMPICILLIN 2G
70594-0088-01	AMPICILLIN 10G
70594-0089-02	CEFEPIME HYDROCHLORIDE 1G
70594-0090-02	CEFEPIME HYDROCHLORIDE 2G
70594-0094-02	CEFTRIAXONE 250MG
70594-0095-02	CEFTRIAXONE 500MG
70594-0096-02	CEFTRIAXONE 1GM
70594-0097-02	CEFTRIAXONE 2GM
70594-0098-01	CEFTRIAXONE 10GM
70594-0114-02	BUPIVACAINE HCL 2.5MG/ML
70594-0117-02	BUPIVACAINE HCL 5MG/ML

If a Covered Entity believes they are due a refund and are not contacted by 11/15/2023, you may contact Xellia at [340b.refunds@xellia.com](mailto:340b.refunds@xellia.com).